A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer

Investigational New Drugs

Volumn 27, Issue 1, 2009, Pages 75-81

  Kindler, Hedy Lee ^a   Burris III, Howard A ^b   Sandler, Alan B ^c   Oliff, Ira Anton ^d  

^a UNIVERSITY OF CHICAGO   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d Hematology Oncology Associates of Illinois   (United States)

Author keywords

L alanosine; Mesothelioma; Methylthioadenosine phosphorylase; Mucositis

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; ALANOSINE; 5'-METHYLTHIOADENOSINE PHOSPHORYLASE; ADENINE; ALANINE; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DYSPNEA; ENZYME DEFICIENCY; FATIGUE; FEMALE; FEVER; HUMAN; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OSTEOSARCOMA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; STOMATITIS; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING; ADOLESCENT; DRUG ADMINISTRATION; ENZYMOLOGY; METABOLISM; NEOPLASM;

ADENINE; ADOLESCENT; ADULT; AGED; ALANINE; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE;

EID: 62749120322     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9160-1     Document Type: Article

References (27)

1. EL Powell LM Leoni MI Canto 2005 Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications Am J Surg Pathol 29 1497 1504 (Pubitemid 41513300)
2. PB Illei VW Rusch MF Zakowski 2003 Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas Clin Cancer Res 9 2108 2113 (Pubitemid 36687632)
3. TJ M'soka J Nishioka A Taga 2000 Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay Leukemia 14 935 940 (Pubitemid 30235074)
4. M Schmid D Malicki T Nobori 1998 Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC) Oncogene 17 2669 2675 (Pubitemid 28544709)
5. Y Hori H Hori Y Yamada 1998 The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia Int J Cancer 75 51 56 (Pubitemid 28113977)
6. T Nobori JG Karras RF Della 1991 Absence of methylthioadenosine phosphorylase in human gliomas Cancer Res 51 3193 3197
7. I Behrmann S Wallner W Komyod 2003 Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma Am J Pathol 163 683 690 (Pubitemid 36909429)
8. JM Garcia-Castellano A Villanueva JH Healey 2002 Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma Clin Cancer Res 8 782 787 (Pubitemid 34742108)
9. W Li D Su H Mizobuchi 2004 Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells Oncol Res 14 373 379 (Pubitemid 39070678)
10. SR Hustinx LM Leoni CJ Yeo 2005 Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion Mod Pathol 18 959 963 (Pubitemid 41059957)
11. SR Hustinx RH Hruban LM Leoni 2005 Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy Cancer Biol Ther 4 83 86 (Pubitemid 41350936)
12. YK Murthy JE Thiemann C Coronelli 1966 Alanosine, a new antiviral and antitumour agent isolated from a Streptomyces Nature 211 1198 1199
13. A Batova MB Diccianni M Omura-Minamisawa 1999 Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro Cancer Res 59 1492 1497 (Pubitemid 29160116)
14. H Harasawa Y Yamada M Kudoh 2002 Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL) Leukemia 16 1799 1807 (Pubitemid 35050111)
15. T Efferth H Miyachi HG Drexler 2002 Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells Blood Cells Mol Dis 28 47 56 (Pubitemid 34408987)
16. J Rubin V Hineman CG Moertel 1983 A phase II study of alanosine in advanced large bowel carcinoma Am J Clin Oncol 6 191 193
17. ET Creagan AJ Schutt JN Ingle 1983 Phase II clinical trial of L-alanosine in advanced upper aerodigestive cancer Cancer Treat Rep 67 1047 (Pubitemid 14208714)
18. ET Creagan HJ Long DL Ahmann 1984 Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma Am J Clin Oncol 7 543 544 (Pubitemid 15176883)
19. PJ Elson LK Kvols SE Vogl 1988 Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma Invest New Drugs 6 97 103 (Pubitemid 18171640)
20. DD Von Hoff SJ Green JA Neidhart 1991 Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study Invest New Drugs 9 87 88
21. J Yu 2001 Alanosine (UCSD) Curr Opin Investig Drugs 2 1623 1630 (Pubitemid 33085503)
22. KS McCarty Jr LS Miller EB Cox 1985 Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies Arch Pathol Lab Med 109 716 721 (Pubitemid 16237466)
23. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 (Pubitemid 19099520)
24. GM Dosik D Stewart M Valdivieso 1982 Phase I study of L-alanosine using a daily x 3 schedule Cancer Treat Rep 66 73 76 (Pubitemid 12254667)
25. MA Goldsmith T Ohnuma M Spigelman 1983 Phase I study of L-alanosine (NSC 15353) Cancer 51 378 380 (Pubitemid 13185361)
26. A Batova H Cottam J Yu 2006 EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine Blood 107 898 903 (Pubitemid 43156285)
27. J Yu A Batova L Shao 1997 Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem/progenitor cells: its therapeutic implication for MTAP (-) malignancies Clin Cancer Res 3 433 438 (Pubitemid 27158068)